Home Journals Articles Updates About
CN
image
收藏切换
Research progress of tepotinib in non-small cell lung cancer
收藏切换
PDF
Ji-wei SHEN1, 2, Shuang WU1, Rui YANG1, Xin WANG1, Xin-yu ZHANG1, Mei-ying DUO1, Ju LIU1, 2
Chinese Journal of Clinical Pharmacology | 2025, 41(4) : 576 - 580
Less
收藏切换
Chinese Journal of Clinical Pharmacology | 2025, 41(4): 576-580
• Review •
Research progress of tepotinib in non-small cell lung cancer
Full
Ji-wei SHEN1, 2, Shuang WU1, Rui YANG1, Xin WANG1, Xin-yu ZHANG1, Mei-ying DUO1, Ju LIU1, 2
Affiliations
  • 1.School of Pharmacy, Liaoning University, Shenyang 110036, Liaoning Province, China
  • 2.Liaoning Provincial Engineering Research Center for Small Molecule Targeted Drug, Shenyang 110036, Liaoning Province, China
Published: 2025-02-28 doi: 10.13699/j.cnki.1001-6821.2025.04.026
Outline
收藏切换

A common carcinogenic mechanism in non-small cell lung cancer (NSCLC) is a jump mutation in exon 14 of the mesenchymal epithelial transition factor (MET) gene, which is commonly present in NSCLC cases and accelerates cancer progression. Clinical studies have shown that tepotinib, as the first oral tyrosine kinase inhibitor targeting MET, exhibits significant efficacy in advanced NSCLC, with an overall response rate (ORR) of 44.7% and a median progression free survival (PFS) of 8.9 to 12.2 months. Although drug resistance appears within 6 to 12 months after treatment, combined treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) can overcome some of the resistance caused by EGFR mutations and MET expansion. In addition, tepotinib has good safety in different patient populations, with common adverse reactions including peripheral edema, nausea, and diarrhea. Tepotinib significantly prolongs the PFS of patients. In addition, other novel MET-TKI such as carbamatinib and sevotinib have also shown good efficacy in the treatment of MET mutant NSCLC. This article summarizes the pharmacological effects, resistance mechanisms, adverse reactions, and clinical application progress of terbotinib in NSCLC.

tepotinib  /  mesenchymal-epithelial transition factor kinase inhibitor  /  pharmacological effects  /  synthetic route  /  clinical evaluation  /  adverse drug reaction
Ji-wei SHEN, Shuang WU, Rui YANG, Xin WANG, Xin-yu ZHANG, Mei-ying DUO, Ju LIU. Research progress of tepotinib in non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology, 2025 , 41 (4) : 576 -580 . DOI: 10.13699/j.cnki.1001-6821.2025.04.026
Appendix
Less
Year 2025 volume 41 Issue 4
PDF
1
0
Cite this Article
BibTeX
Article Info
doi: 10.13699/j.cnki.1001-6821.2025.04.026
  • Receive Date：2024-08-15
  • Online Date：2026-08-04
  • Published：2025-02-28
Article Data
Affiliations
History
  • Received：2024-08-15
Funding
Affiliations
    1.School of Pharmacy, Liaoning University, Shenyang 110036, Liaoning Province, China
    2.Liaoning Provincial Engineering Research Center for Small Molecule Targeted Drug, Shenyang 110036, Liaoning Province, China
References
Share
https://castjournals.cast.org.cn/joweb/zglcylxzz/EN/10.13699/j.cnki.1001-6821.2025.04.026
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House